EDX Medical Group PLC (LSE:EDX), the Cambridge-based diagnostics developer that moved to AIM in May, has signed what it describes as a significant commercial agreement, a three-year employee health screening contract with car dealership group Arnold Clark. Announced on 17 September 2026, the deal is expected to generate annual revenue of £1.4m to £1.6m, more than the company's entire expected revenue for its last financial year.
What the company does
EDX Medical develops and supplies digital diagnostic products and services aimed at the early detection and treatment of major diseases. Its offering includes biomarker testing panels, prostate cancer testing and an employee health screening service that combines blood tests with general health and family history questionnaires. The company was founded by Professor Sir Chris Evans, a veteran biotechnology entrepreneur and its largest shareholder.
Latest developments
Under the Arnold Clark agreement, EDX will run a voluntary health and wellbeing screening programme for the group's 11,600 employees across 200 UK locations. The company says its biomarker panels cover more than 220 disease conditions, including cancer, cardiovascular disease and metabolic disorders. Testing sessions are due to begin in October 2026. Arnold Clark had earlier hosted prostate cancer testing for male staff as part of the Scottish Prostate Cancer Initiative, which EDX delivers.
The contract followed agreements in principle with three significant UK employers, first announced in July, and EDX has said it is in talks with other large companies. Sir Chris Evans called the deal a very significant endorsement of the company's science and logistics.
The company's shares began trading on AIM on 13 May 2026, having moved from the Apex segment of the Aquis Stock Exchange through the streamlined AIM Designated Market route. EDX said the move should improve access to capital, liquidity and investor visibility.
Financial and dividend picture
For the year to 31 March 2026, EDX has said it expects revenue of about £1.2m, against £122,608 the previous year, driven mainly by distribution of prostate cancer tests. The board deferred £860,000 of revenue into the current year after discussions with auditors, because order processing ran beyond the year end. Cash at the end of March was about £2.9m.
In August, the company raised about £2.7m through a subscription for 19,378,563 shares at 14p each, with attached warrants, to expand the screening service. It also has a working capital facility of up to £3.71m from Sir Chris Evans, in addition to an existing £2.0m loan from him. EDX has said it does not expect to pay dividends in the short to medium term.
Sector and index context
As one of the newest constituents of the FTSE AIM All Share Index, EDX joins a crowded group of small healthcare and diagnostics companies on the market. Employer-funded health screening is a growing area, with businesses looking to reduce sickness absence, which official statistics show costs the UK economy heavily each year.
Key risks
EDX remains at an early commercial stage and has reported losses, so it depends on new contracts, share issues and support from its founder. Revenue could fall short if employee participation is lower than expected. Regulatory approval delays have previously held back some tests, and the company relies on a small number of customers and partners.
What to watch next
Key points include the start of Arnold Clark testing in October, conversion of the other employer agreements into contracts, audited results for the year to March 2026 and evidence that revenue can scale towards profitability.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...